<DOC>
	<DOCNO>NCT01182675</DOCNO>
	<brief_summary>The goal study develop novel approach hematopoietic stem cell transplantation child Severe Combined Immunodeficiency Disease ( SCID ) eliminate use toxic chemotherapy conditioning maximize likelihood T B cell immune reconstitution . Rather classic chemotherapeutic agent , investigator utilize targeted stem cell mobilizer , plerixafor , combination alemtuzumab , monoclonal antibody . Correlative scientific question include : 1 ) efficacy characteristic host stem cell mobilization ; 2 ) alemtuzumab pharmacokinetics young child .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplantation ( HSCT ) Children With SCID Utilizing Alemtuzumab , Plerixafor &amp; Filgrastim</brief_title>
	<detailed_description>The goal study develop approach hematopoietic stem cell transplantation child Severe Combined Immunodeficiency Disease ( SCID ) eliminate use toxic chemotherapy conditioning maximize likelihood T B cell immune reconstitution . SCID rare primary immunodeficiency disease multiple genotype phenotype , depend various factor include presence B cell NK cell , presence maternal cell patient 's circulation , numerous way approach transplant . The major issue must address approach transplantation SCID graft rejection T B cell immune reconstitution . Depending specific SCID diagnosis , phenotype , presence maternal engraftment diagnosis , evaluate two transplant approach attempt optimize engraftment donor HSC likelihood T B cell reconstitution eliminate use toxic chemotherapy conditioning . 1 . Primary Objective : To determine administration plerixafor &amp; filgrastim ( G-CSF ) prior stem cell infusion result increase donor stem cell occupancy available bone marrow niche B-cell engraftment patient SCID . 2 . Secondary Objectives : . To determine NK cell depletion Alemtuzumab overcome NK-mediated graft resistance haplocompatible transplant NK+ SCID . ii . To determine optimal dose Alemtuzumab young child . iii . To determine immunophenotypic characteristic CD34+ cell mobilize engrafted patient receive plerixafor &amp; filgrastim prior HCT . iv . To determine thymic output , measure T-cell receptor excision circle , patient receive haplocompatible transplant &amp; boost .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients classic SCID phenotype ( &lt; 400 CD3/ul maternally engraft &lt; 10 % normal PHA lymphoproliferative response ) . Genotypic identification preferable , require . Patients must acceptable stem cell donor ( HLA match relative , 9 10/10 HLAmatched unrelated , haplocompatible relative ) . Patients `` leaky '' SCID syndrome , Omenn 's Syndrome , reticular dysgenesis , ADA deficiency Lansky score &lt; 60 % Patient expect survival &lt; 4 week ( include disseminate CMV infection involve lung and/or CNS )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>SCID</keyword>
	<keyword>Transplant</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Plerixafor</keyword>
</DOC>